17 August 2020
Starpharma today announced that it has signed a new research partnership with leading Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical Co., Ltd[1]. (stock code 300026; Chase Sun), to develop several DEP® nanoparticle formulations for an anti-infective drug. The agreement also provides for the potential to conduct additional DEP® programs, which can be across therapeutic areas beyond anti-infectives.
Under this new DEP® partnership, Starpharma will initially develop DEP® nanoparticle formulations for an anti-infective product for Chase Sun with the view of enhancing its performance and expanding its therapeutic utility. Chase Sun will fund all activities under this agreement and all costs associated with the further development of any DEP® product. In the event that Chase Sun wishes to commercialise any of the resultant DEP® products, a DEP® licence agreement will be entered into with Starpharma.
Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to sign this new DEP® partnership with Chase Sun. Chase Sun are a rapidly growing and innovative company in an important global market. This agreement illustrates the broad applicability of the DEP® platform and will further develop the commercial potential of DEP® in the anti-infective space, a therapeutic area of growing interest and need.”
Chase Sun is a leading listed Chinese pharmaceutical company focussed on R&D and commercialisation of healthcare products and operates in one of the largest markets in the world, with more than 6,000 employees. Chase Sun’s market capitalisation exceeds A$3 billion (stock code 300026) and its 2019 sales were in excess of A$1.012 billion.
Download full announcement: Starpharma signs new DEP® partnership with Chase Sun
